

**Remarks/Arguments:**

In response to the restriction requirement, Applicants elect the invention of group I which is encompassed by Claims 1, 3, 4, 6, 8, 9, 10, 11, 18, 20, 21 and 23. Applicants have amended Claims 1, 3, 10, 18, 20, and 21 to comply with the restriction requirement.

Claims 2, 5, 7, 12-15, and 22 have been canceled.

Claims 16, 17, and 19 are withdrawn.

The above amendments have been made without prejudice to Applicants right to prosecute any cancelled subject matter in a timely filed continuation application.

Applicants believe the application is in condition for allowance, which action is respectfully requested.

A petition for a one month extension of time is being filed herewith, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 100936-1P US.

Although Applicants believe no excess claim fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 100936-1P US.

Respectfully submitted,  
/Theresa Devlin/

---

Name: Theresa Devlin  
Dated: June 3, 2008  
Reg. No.: 45,361  
Phone No.: 781-839-4969  
Global Intellectual Property, Patents,  
AstraZeneca R&D Boston,  
35, Gatehouse Drive,  
Waltham,  
MA 02451